A recent phase I-II study revealed that the combination of trastuzumab and pertuzumab exhibited only modest antitumor activity in advanced HER2-mutated NSCLC patients after multiple treatments [124]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.